Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?. (December 2021)

• Record Type: Journal Article
• Authors: Papeix, Caroline; Mazoyer, Julie; Maillart, Elisabeth; Bensa, Caroline; Dubessy, Anne-Laure; Goujon, Catherine; Launay, Odile; Lebrun-Frénay, Christine; Louapre, Céline; Mrejen, Serge; Pourcher, Valérie; Rosenheim, Michel; Stankoff, Bruno; Vidal, Jean-Sebastien; Lubetzki, Catherine
• Is Part Of: Multiple sclerosis. Volume 27:Number 14(2021)
• Page Start: 2280
• Page End: 2283
• Publication Date: 2021-12
• Subjects: Vaccination -- yellow fever -- travel -- multiple sclerosis -- yellow fever vaccination; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/13524585211006372
• Languages: English
• ISSNs: 1352-4585

Abstract

Background: Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses. Objective: To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV. Methods: Non-interventional observational retrospective, exposed/non-exposed cohort study nested in the French national cohort including MS. Results: 128 RR-MS were included. The 1-year annualized relapse rate (ARR) following YFV did not differ between exposed: 0.219 (0.420) and non-exposed subjects: 0.208 (0.521) ( p = 0.92). Time to first relapse was not different between groups (adjusted hazard ratio (HR) = 1.33; 95% confidence interval (CI) = 0.53–3.30, p = 0.54). Conclusion: These results suggest that YFV does not worsen the course of RR-MS.